Related Experiment Video
Updated: Jan 9, 2026

A Porcine Model of Acute Autologous Pulmonary Embolism
Published on: September 6, 2024
Advancements in Pulmonary Embolism Management: Current Approaches and Future Directions
Carlo Banfi1,2, Carolina Montonati3, Alfonso Ielasi4
1Department of Cardiothoracic Surgery, IRCCS Ospedale Galeazzi-Sant'Ambrogio, University of Milan, 20157 Milan, Italy.
Pulmonary embolism (PE) poses a high mortality risk. Current treatment often deviates from guidelines due to patient comorbidities, prompting exploration of novel therapies for better pulmonary embolism management.
Area of Science:
- Cardiology
- Pulmonology
- Medical Research
Background:
- Pulmonary embolism (PE) is a significant cause of cardiovascular death.
- High 30-day mortality rates are associated with PE.
- Clinical practice for PE management frequently deviates from established guidelines.
Purpose of the Study:
- To review the current epidemiology of pulmonary embolism.
- To outline initial assessment and conventional treatment strategies for PE.
- To explore novel and emerging therapeutic approaches for PE management.
Main Methods:
- Literature review of current epidemiology.
- Analysis of standard-of-care treatment options.
- Exploration of emerging therapies for PE.
Main Results:
- PE remains a leading cause of cardiovascular mortality.
- Comorbidities in PE patients complicate adherence to treatment guidelines.
- Novel therapies are under investigation to improve PE outcomes.
Conclusions:
- There is a gap between PE treatment guidelines and clinical practice.
- Patient comorbidities are a key factor in treatment deviations.
- Emerging therapies may offer improved management strategies for pulmonary embolism.
Related Concept Videos
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Pulmonary Embolism III: Nursing Management
Pulmonary Embolism I: Introduction
Venous Thrombosis III: Interprofessional Care
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

